Table 2. Mean parameters and IIV corresponding to the structural pharmacodynamic model.
| Study |
Present study
|
Friberg et al (2002)
|
||
|---|---|---|---|---|
| parameters | Estimate | RSE (%) | Estimate | RSE (%) |
| Circ0 (109 l−1) | 4.41 | 6.3 | 5.05 | 1.9 |
| IIV Circ0 (%) | 49.2 | 18.3 | 42 | 7 |
| MTT (h) | 96.2 | 8.8 | 88.7 | 2.5 |
| IIV MTT (%) | 25.5 | 40.2 | 16 | 24 |
| γ | 0.146 | 42.5 | 0.161 | 3.7 |
| Slope (μg−1 ml) | 7.76 | 7.4 | 10.6 | 5.2 |
| IIV Slope (%) | 96.5 | 42 | 60 | 14 |
| Proportional residual error (%) | 35.6 | 21.3 | 27.3 | — |
| Additive residual error (ANC 109 l−1) | Not applicable | — | 1.15 | — |
Circ0=baseline circulating cell counts before drug administration; γ=power factor for the feedback mechanism; IIV=interindividual variability; MTT=mean transit time through the maturation delay chain; RSE=relative standard error related to the corresponding variance term; Slope=drug sensitivity.
Values of the present study and those previously obtained by Friberg et al (2002) for docetaxel.